The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis

被引：171

作者：

Harper, Charles R. ^{[1
]}

Jacobson, Terry A. ^{[1
]}

机构：

[1] Emory Univ, Dept Med, Off Hlth Promot & Dis Prevent, Atlanta, GA 30303 USA

来源：

CURRENT OPINION IN LIPIDOLOGY | 2007年 / 18卷 / 04期

关键词：

myopathy; rhabdomyolysis; safety; statin;

D O I：

10.1097/MOL.0b013e32825a6773

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

It is important to maintain perspective by looking at the impact of statin myopathy relative to the impact of preventing atherosclerotic complications. The potential benefits of therapy must outweigh the risks, In the case of statin therapy the benefit/risk ratio is overwhelmingly positive.

引用

页码：401 / 408

页数：8

共 35 条

[1] Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: Results of a national survey [J].

Ansell, Benjamin J. ;

Fonarow, Gregg C. ;

Maki, Kevin C. ;

Dicklin, Mary R. ;

Bell, Margie ;

Davidson, Michael H. .

AMERICAN HEART JOURNAL, 2006, 152 (05) :976-981

[2] Molecular clues into the pathogenesis of statin-mediated muscle toxicity [J].

Baker, SK .

MUSCLE & NERVE, 2005, 31 (05) :572-580

[3] Risk for myopathy with statin therapy in high-risk patients [J].

Ballantyne, CM ;

Corsini, A ;

Davidson, MH ;

Holdaas, H ;

Jacobson, TA ;

Leitersdorf, E ;

März, W ;

Reckless, JPD ;

Stein, EA .

ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (05) :553-564

[4] Statin safety: An overview and assessment of the data-2005 [J].

Bays, H .

AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :6C-26C

[5] Statin safety and drug interactions: Clinical implications [J].

Bottorff, MB .

AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :27C-31C

[6] Benefit-risk assessment of rosuvastatin 10 to 40 milligrams [J].

Brewer, HB .

AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (4B) :23K-29K

[7] Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study [J].

Bruckert, E ;

Hayem, G ;

Dejager, S ;

Yau, C ;

Bégaud, B .

CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (06) :403-414

[8]

Dirks Amie J, 2006, Am J Physiol Cell Physiol, V291, pC1208

[9] Effects of HMG-CoA reductase inhibitors on skeletal muscle - Are all statins the same? [J].

Evans, M ;

Rees, A .

DRUG SAFETY, 2002, 25 (09) :649-663

[10] Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro [J].

Flint, OP ;

Masters, BA ;

Gregg, RE ;

Durham, SK .

TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 145 (01) :91-98

← 1 2 3 4 →